Responses
Clinical and epidemiological research
Extended report
Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)
Compose a Response to This Article
Other responses
No responses have been published for this article.